Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.54 |
| ▸ | RET | P07949 | 5/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354726 | 0.87 | GPR119 (0.56) | GPR119RETTBK1IKBKEJAK2 | |
| SCHEMBL354865 | 0.86 | GPR119 (0.55) | GPR119TBK1IKBKEJAK2JAK1 | |
| SCHEMBL23220924 | 0.79 | MEN1 (0.49) | GPR119RETNR1H2NR1H3EGLN2 | |
| SCHEMBL354800 | 0.78 | TP53 (0.47) | RETTBK1IKBKENPY2RTP53 | |
| SCHEMBL355300 | 0.78 | BACE1 (0.55) | GPR119RETNR1H2NR1H3EGLN2 | |
| SCHEMBL2123650 | 0.77 | S1PR1 (0.49) | GPR119HDAC4 | |
| SCHEMBL2122654 | 0.76 | S1PR1 (0.48) | GPR119HDAC4 | |
| SCHEMBL16112423 | 0.76 | RET (0.56) | RETNR1H2NR1H3 | |
| SCHEMBL652725 | 0.75 | MEN1 (0.52) | GPR119RETNR1H2NR1H3EGLN2 | |
| SCHEMBL594432 | 0.75 | MAPT (0.54) | GPR119RETNR1H2NR1H3EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | GPR119 58/4885RET 608/4885TBK1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.